Overall, 80% of subjects with NAFLD were positive for at least one variant in GCKR, 31% for LYPLAL1, 15% for NCAN, 8% for PPP1R3B and 14% for TM6SF2 genes. This evidence concerns the gene TM6SF2 and metabolic dysfunction-associated steatotic liver disease.